New Data Show Ceftobiprole Comparable to Daptomycin in Staphylococcus aureus Bacteremia

The study demonstrated that ceftobiprole achieved overall treatment success rates comparable to daptomycin in patients with Staphylococcus aureus bacteremia, with similar outcomes observed in both MRSA and MSSA subgroups (approximately 69–71%). These findings suggest that efficacy is consistent across major S aureus phenotypes and aligns closely with the established performance of daptomycin in this indication.

Importantly, these results contributed to regulatory approvals in multiple regions, including the FDA and EMA, positioning ceftobiprole as an alternative therapeutic option for S. aureus bacteremia with a labeled indication similar to daptomycin.

In real-world practice, clinicians are likely to interpret these data as expanding treatment flexibility rather than replacing existing therapies. The key clinical implication is that ceftobiprole may be most impactful in MRSA bacteremia, where it represents a novel beta-lactam/cephalosporin-class option—a significant development given the lack of previously approved beta-lactams for MRSA. For MSSA infections, however, established agents such as cefazolin remain strong first-line choices, meaning ceftobiprole is less likely to shift standard practice in that setting.

Disclaimer: Holland was the Chair of Adjudication for the ERADICATE trial.

This video series has been produced independently by Contagion Live and supported through a educational grant by Innoviva Specialty Therapeutics inc